Although hypokalemia, anemia, a decrease in platelet count, prolonged PT, a decrease in anti-thrombin III, and hematuria were also observed in three of four patients, there was no apparent evidence for a causal relationship between these adverse events and rh-HGF administration. The gene discussed is HGF; the disease is anemia (phenotype).